SNORD76: A Drug Target and Biomarker for Various Diseases (G692196)

Target Name: SNORD76

NCBI ID: G692196

SNORD76

Other Name(s): U76 | small nucleolar RNA, C/D box 76 | Small nucleolar RNA, C/D box 76

SNORD76: A Drug Target and Biomarker for Various Diseases

SNORD76 (U76) is a drug target and a biomarker that is being studied for its potential role in treating various diseases, including cancer, neurodegenerative diseases, and respiratory disorders. SNORD76 is a small non-coding RNA molecule that has been shown to play a role in regulating gene expression and has been identified as a potential drug target in multiple disease models.

The discovery and characterization of SNORD76 began in the late 1990s when researchers identified a unique RNA molecule in the brain that was expressed in low levels and was highly conserved across different species. The RNA molecule was later shown to play a role in the regulation of gene expression and was named SNORD76.

Since its discovery, SNORD76 has been shown to be involved in a wide range of physiological processes, including cell growth, differentiation, and apoptosis (programmed cell death). The molecule has also been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and respiratory disorders.

One of the key challenges in studying SNORD76 is its high conservation, as it is highly conserved across different species, making it difficult to study its function in specific contexts. However, research groups have made significant progress in understanding the biology of SNORD76 and its potential as a drug target.

In the context of cancer, SNORD76 has been shown to play a role in the regulation of cell cycle progression, apoptosis, and angiogenesis (the formation of new blood vessels). Several studies have shown that SNORD76 can inhibit the activity of oncogenes, such as p53, which is a well-known tumor suppressor gene that plays a critical role in preventing the formation of cancer cells.

Another study also showed that SNORD76 can promote the apoptosis of cancer cells, which is a natural mechanism that helps the body eliminate damaged or dysfunctional cells. The researchers suggested that SNORD76 may be a useful drug target for cancer treatment.

In the context of neurodegenerative diseases, SNORD76 has been shown to play a role in the regulation of neurotransmitter synthesis and release, as well as in the regulation of ion channels and neurotransmitter receptors. The molecule has been shown to interact with dopamine, a neurotransmitter that plays a critical role in motivation, pleasure, and mood regulation.

In addition, SNORD76 has also been shown to be involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. Several studies have shown that SNORD76 can influence the formation of new synapses and the regulation of neurotransmitter release in the brain.

In the context of respiratory disorders, SNORD76 has been shown to play a role in the regulation of airway epithelial cell function, including the regulation of ion channels and the production of pro-inflammatory cytokines. The molecule has been shown to interact with the transcription factor , NF-kappa-B, which plays a critical role in the regulation of inflammation and fibrosis.

In conclusion, SNORD76 is a promising drug target and biomarker that has the potential to treat a wide range of diseases. Further research is needed to fully understand the biology of SNORD76 and its role in various disease contexts.

Protein Name: Small Nucleolar RNA, C/D Box 76

The "SNORD76 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD76 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets